Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers-Reference-Cited by-同舟云学术

Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers

Published:2022-11-24 Issue:6 Volume:12 Page:6811-6824
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Tao Hao‐Yun¹^ORCID,He Fang²,Shi Qi‐Yun³,Liu Ran⁴,Wang Zhi‐Long⁵,Du Kun‐Peng¹,Li Jian‐Feng¹,Liu Hui¹,Lu Zhi‐Qiang²,Zhang Jing‐Jing²,Bai Yu‐Hai²

Affiliation:

1. Department of Radiation Oncology Guangzhou Medical University Cancer Center Guangzhou China

2. Department of Radiation Oncology People's Hospital of Zhongshan City Zhongshan China

3. Department of Breast and Thyroid Surgery, Southwest Hospital Army Medical University Chongqing China

4. Department of Pediatrics LongHua District People's Hospital Shenzhen China

5. Department of Radiology People's Hospital of Zhongshan City Zhongshan China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5470

Reference48 articles.

1. Nasopharyngeal carcinoma

2. Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy

3. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy

4. National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: head and neck cancers. Version 2 2022.https://www.nccn.org/professionals/physician_gls/pdf/head‐and‐neck.pdf.

5. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial